Key facts
- Guilford Street Laboratories’s last known valuation is $4.5M (Mar 2025).
- It has raised $490K; the latest was Early Stage VC ($490K) in Mar 2025.
- Notable investors include UCL Business, University College London.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Guilford Street Laboratories
- ·The full record, as it builds
Funding rounds
No funding rounds for Guilford Street Laboratories are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Guilford Street Laboratories
Operator of a biotechnology company intended to offer machine learning-powered mass spectrometry to develop biomarker assays. The company offers highly precise and sensitive biomarker assays developed through machine learning-driven mass spectrometry, specializing in protein, lipid and metabolite analysis, enabling clients to gain crucial data for a comprehensive examination of all relevant endpoints and propel their research forward.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2023
- Employees
- 3
- Website
- guilfordstreetlabs.com/
- Ownership
- Privately Held (backing)
Guilford Street Laboratories doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Guilford Street Laboratories shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Guilford Street Laboratories in its N-PORT filings yet. We sweep new filings monthly.